As reported, only about half of the patients with acquired resistance to first or second‐generation EGFR‐TKIs can accept re‐biopsy, and 30% of the re‐biopsied tumor tissues were found to be insufficient for downstream genotyping.14 Here, EGFR is linked to neoplasm.